For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-09-30 | 2025-06-30 | |
|---|---|---|---|---|
| Research and development | 3,487.247 | 2,589.749 | 1,730 | |
| General and administrative | 1,738.006 | 1,503.326 | 1,504.295 | |
| Total operating expenses | 5,225.253 | 4,093.074 | 3,234.295 | |
| Income (loss) from operations | -5,225.253 | -4,093.074 | -3,234.295 | |
| Other income | - | 0 | - | |
| Interest income (loss) | 1,332.203 | 655.473 | 780.769 | |
| Net income (loss) | -3,893.05 | -3,437.601 | -2,453.526 | |
| Foreign currency translation gain (loss), net | -0.19 | -0.116 | -3.456 | |
| Unrealized gain (loss) on investments, net | -32.678 | -65.763 | 102.817 | |
| Comprehensive income (loss) | -3,925.918 | -3,503.48 | -2,354.165 | |
| Basic EPS | -0.46 | -0.48 | -0.35 | |
| Basic Average Shares | 8,535,443 | 7,123,849 | 6,998,000 | |
Monopar Therapeutics (MNPR)
Monopar Therapeutics (MNPR)